Bryan Griffiths - Böcker

Animal cell technology has undergone a transformation between 1986 and 1996, from a research tool and highly specialized technology to a central resource for innovation in pharmaceutical research and development. These papers bring up to date the historical perspective of animal cell technology for the benefit of society, and aims to charter this technology for the years to come. Strong contributions are grouped in the traditional ESACT areas of cell and physiology engineering dealing with cell state, including genetics, and its environment, and animal cell process engineering covering integration of bioreaction with bioseparation coupled with on-line monitoring to improve protein production and consistency. Extensive coverage of metabolic engineering on synthesis, folding, assembly, transiting and secretion is dealt with in the session on recombinant proteins: biosynthesis and bioprocessing. Two traditional but expanding areas of animal cell technology are highlighted in the broad sessions of animal cells as tools for discovery and testing and animal cell vaccines: present and future.Two final sessions cover the more recent domains of animal cell technology work - tissue engineering and biomedical devices and cells and vectors for genetic medicine.

Animal cell technology is an important part of biotechnology and many products are now used in human health care and for veterinary applications. However, there are many times more products actually in the developmental pipelines of the biotechnology industry, including various phases of clinical trials. The proceedings of the 15th meeting of the European Society For Animal Cell Technology (Tours, France, September 1997) presents the actual current state as well as new Developments and applications in animal cell technology for the benefit of society. These proceedings represent both the current state and applications of animal cell technology and the way the technology is expanding into new areas to give an insight into new products and applications for human and animal health care.

Products from Cells - Cells as Products This book ist he "lasting" product, a resource ofup to date information in the scientific literature fort he field ofanimal cell tec hnology, as it was presented during a pleasant and s timulating mee ting that was held in Lugano Switzerland in April 1999. "Products" appeartwice int he title oft he conference. This clearly indicates the fact that the focus oft he papers presented during this meeting was really the application ofn ew technologies (novel reactors or novel vectors, for example for the preparation and/ort he more efficient generation ofproducts ) that could be used, mainly, int he medical field. Classical approaches forthe use ofa nimal cells, for example forthe p r oduction of virus vaccines for human and animal health, still remain an important technology and still have, surprisingly, quite significant potential for further development and improvement. How ever, it appears that major technological advances an d major growth from an economical point ofview are occurring in other areas.Most importantly, protein production on the basis of recombinant DNA molecules transferred into a nimal cells, appears to be an ever increasing field of interest and innovation, even though the first production scheme with this technology was approved more than 15 years ago.

Products from Cells - Cells as Products This book ist he "lasting" product, a resource ofup to date information in the scientific literature fort he field ofanimal cell tec hnology, as it was presented during a pleasant and s timulating mee ting that was held in Lugano Switzerland in April 1999. "Products" appeartwice int he title oft he conference. This clearly indicates the fact that the focus oft he papers presented during this meeting was really the application ofn ew technologies (novel reactors or novel vectors, for example for the preparation and/ort he more efficient generation ofproducts ) that could be used, mainly, int he medical field. Classical approaches forthe use ofa nimal cells, for example forthe p r oduction of virus vaccines for human and animal health, still remain an important technology and still have, surprisingly, quite significant potential for further development and improvement. How ever, it appears that major technological advances an d major growth from an economical point ofview are occurring in other areas.Most importantly, protein production on the basis of recombinant DNA molecules transferred into a nimal cells, appears to be an ever increasing field of interest and innovation, even though the first production scheme with this technology was approved more than 15 years ago.

Animal cell technology has undergone a rapid transformation over the last decade from a research tool and highly specialised technology to a central resource for innovation in pharmaceutical research and development. These proceedings of the 14th Meeting of the European Society for Animal Cell Technology (Vilamoura, Portugal, May 1996) bring up to date the historical perspective of animal cell technology for the benefit of society, `From Vaccines to Genetic Medicine', and will charter this vital technology for the years to come. Strong contributions are grouped in the traditional ESACT areas of 'Cell and Physiology Engineering' dealing with cell state, including genetics, and its environment, and 'Animal Cell Process Engineering' covering integration of bioreaction with bioseparation coupled with on-line monitoring to improve protein production and consistency. Extensive coverage of metabolic engineering on synthesis, folding, assembly, transiting and secretion is dealt with in the session on 'Recombinant Proteins: Biosynthesis and Bioprocessing'. Two traditional but expanding areas of animal cell technology relevance are highlighted in the broad sessions of 'Animal Cells as Tools for Discovery and Testing' and 'Animal Cell Vaccines: Present and Future'. Two sessions finally cover the more recent domains of animal cell technology work - 'Tissue Engineering and Biomedical Devices' and 'Cells and Vectors for Genetic Medicine' - where one can foresee a very bright future.